Boyle Scott N 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics (CCCC) CBO Scott N. Boyle Receives 200,000 RSUs
What Happened
Scott N. Boyle, Chief Business Officer of C4 Therapeutics (CCCC), received a 200,000‑share restricted stock unit (RSU) award on Feb 13, 2026 (grant reported at $0). In addition, he acquired 5,000 shares on Feb 13 and 20,950 shares on Feb 14 through exercise/conversion of derivatives (each reported at $0). The issuer withheld 1,735 and 7,269 shares on those dates to satisfy tax withholding obligations at $1.89 per share (cash value of withheld shares: $3,279 and $13,738, respectively; total ≈ $17,017). Net new shares received (acquired minus withheld) = 216,946 shares. These were compensation/vesting-related transactions rather than open‑market purchases or sales.
Key Details
- Transaction dates: Feb 13–14, 2026; Form 4 filed Feb 18, 2026 (period of report Feb 13, 2026).
- Grants/acquisitions: 200,000 RSUs granted (A) @ $0; 5,000 (M) and 20,950 (M) shares acquired @ $0.
- Tax withholding/dispositions: 1,735 and 7,269 shares withheld (F) at $1.89/share = $3,279 and $13,738 (total ≈ $17,017). These withheld shares are not a sale by the reporting person (see footnote).
- Net shares added to Boyle’s position (per this filing): 216,946 (225,950 acquired − 9,004 withheld).
- Shares owned after the transaction: not specified in the filing.
- Footnotes: F1 describes the 200,000 RSU vesting schedule (100,000 vest in three annual installments starting Feb 13, 2027; 100,000 vest in full Feb 13, 2029 subject to performance). F2 notes some acquired shares reflect vesting of previously disclosed RSU grants. F3 clarifies withheld shares satisfy tax withholding and do not represent a sale by the reporting person.
- Filing timeliness: filing shows Feb 18, 2026 submission for Feb 13–14 transactions (appears timely).
Context
- Code M indicates exercise/conversion of derivatives (here, conversion/exercise at $0), and the withheld shares show a net‑settlement for tax purposes rather than an open‑market sale.
- These entries are compensation/vesting events (routine for executives) and should be interpreted as such; they do not by themselves indicate a change in the insider’s investment view.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-13+200,000→ 307,805 total - Exercise/Conversion
Common Stock
[F2]2026-02-13+5,000→ 307,805 total - Tax Payment
Common Stock
[F3]2026-02-13$1.89/sh−1,735$3,279→ 306,070 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+20,950→ 306,070 total - Tax Payment
Common Stock
[F2]2026-02-14$1.89/sh−7,269$13,738→ 298,801 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.